Current Colorectal Cancer Reports

, Volume 7, Issue 3, pp 227–240 | Cite as

Biological Markers in Patients with Early-Stage Colon Cancer: Consensus and Controversies



Colorectal cancer is one of the most common malignancies in the Westernized world. Particularly in the setting of metastatic disease, advances in the use of biomarkers have resulted in “personalized therapy” being an aspect of routine care. However, their role is less clear-cut in the context of adjuvant treatment for early-stage colon cancer. We still largely rely on conventional TNM staging to determine prognosis and treatment options in early-stage disease. Ongoing research is elucidating alternative measures, in the form of prognostic and predictive biomarkers, which may better assist in understanding the wide spectrum of outcomes in early-stage disease; as well as the potential to select and tailor appropriate therapeutic options for an individual rather than simply treating a disease and a “cancer stage”. This review outlines key discoveries and controversies in the application of biomarkers to tailor treatment in early-stage colon cancer.


Colorectal cancer Biomarkers K-ras B-raf Prognostic Predictive Microsatellite instability Mismatch repair Colon cancer Adjuvant Chemotherapy Chromosomal instability CIMP 


Papers of particular interest, published recently, have been highlighted as: •Of importance •• Of major importance

  1. 1.
    Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol. 2004;22(10):1797–806.PubMedCrossRefGoogle Scholar
  2. 2.
    AJCC Colon and Rectum Cancer Staging, 7th edition (summary poster). Available from: Accessed April 2011.
  3. 3.
    AJCC Cancer Staging Manual: Summary of changes from the sixth edition to the seventh. Available from: Accessed April 2011.
  4. 4.
    • Wilkinson NW, Yothers G, Lopa S, et al.: Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials. Ann Surg Oncol 2010;17(4):959–66. This article describes a pooled analysis of 2966 patients from five NSABP trials, comparing adjuvant chemotherapy with surgery alone for stage II and III colon cancer. PubMedCrossRefGoogle Scholar
  5. 5.
    Foundation for the National Institutes of Health: The Biomarkers Consortium. Available from: Accessed February 2011.
  6. 6.
    Kondo Y, Issa JP. Epigenetic changes in colorectal cancer. Cancer Metastasis Rev. 2004;23(1–2):29–39.PubMedCrossRefGoogle Scholar
  7. 7.
    Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009;100(2):266–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Raut CP, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 2004;568(2):275–82.PubMedGoogle Scholar
  9. 9.
    Kim H, Jen J, Vogelstein B, Hamilton SR. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145(1):148–56.PubMedGoogle Scholar
  10. 10.
    Van Cutsem E, Labianca R, Bodoky G, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009;27(19):3117–25.PubMedCrossRefGoogle Scholar
  11. 11.
    •• Roth AD, Tejpar S, Delorenzi M, et al.: Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial. J Clin Oncol 2010;28(3):466–74. This is a prospectively planned translational study from the PETACC-3 adjuvant colon cancer trial; analysis of tissue from 1564 trial participants. PubMedCrossRefGoogle Scholar
  12. 12.
    •• Hutchins G, Southward K, Handley K, et al.: Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol 2011;29(10):1261–1270 This is a translational study from the QUASAR adjuvant colon cancer trial; analysis of tissue from 1913 trial participants assessing the prognostic and predictive value of MMR deficiency, K-ras, and B-raf mutations. PubMedCrossRefGoogle Scholar
  13. 13.
    Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23(3):609–18.PubMedCrossRefGoogle Scholar
  14. 14.
    Kim GP, Colangelo LH, Wieand HS, et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007;25(7):767–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Malesci A, Laghi L, Bianchi P, et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res. 2007;13(13):3831–9.PubMedCrossRefGoogle Scholar
  16. 16.
    Deschoolmeester V, Van Damme N, Baay M, et al. Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. Eur J Cancer. 2008;44(15):2288–95.PubMedCrossRefGoogle Scholar
  17. 17.
    Lamberti C, Lundin S, Bogdanow M, et al. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer. Int J Colorectal Dis. 2007;22(2):145–52.PubMedCrossRefGoogle Scholar
  18. 18.
    Emterling A, Wallin A, Arbman G, Sun XF. Clinicopathological significance of microsatellite instability and mutated RIZ in colorectal cancer. Ann Oncol. 2004;15(2):242–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138(6):2059–72.PubMedCrossRefGoogle Scholar
  20. 20.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 1990;61(5):759–67.PubMedCrossRefGoogle Scholar
  21. 21.
    Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer. 2005;41(14):2060–70.PubMedCrossRefGoogle Scholar
  22. 22.
    • Walther A, Houlston R, Tomlinson I: Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis. Gut 2008;57(7):941–50. This is a meta-analysis of 63 studies analyzing the prognostic effect of chromosomal instability. PubMedCrossRefGoogle Scholar
  23. 23.
    Bertagnolli M, Niedzwiecki D, Hall M, et al.: Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581. j Clin Oncol 2009, 27:15s, (suppl; abstract 4012)CrossRefGoogle Scholar
  24. 24.
    Popat S, Zhao D, Chen Z, et al. Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients. Anticancer Res. 2007;27:627–33.PubMedGoogle Scholar
  25. 25.
    Roth A, Klingbiel D, Yan P, et al.: Molecular and clinical determinants of survival following relapse after curative treatment of stage II-III colon cancer (CC): Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial. J Clin Oncol 28:15s, 2010 (suppl; abstr 3504)CrossRefGoogle Scholar
  26. 26.
    Roth AD, Tejpar S, Yan P, et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60–00 trial [abstract 4002]. J Clin Oncol. 2009;27(15 suppl):169s.Google Scholar
  27. 27.
    Weisenberger DJ, Siegmund KD, Campan M, et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. 2006;38(7):787–93.PubMedCrossRefGoogle Scholar
  28. 28.
    Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med. 2009;361(25):2449–60.PubMedCrossRefGoogle Scholar
  29. 29.
    Barault L, Charon-Barra C, Jooste V, et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases. Cancer Res. 2008;68(20):8541–6.PubMedCrossRefGoogle Scholar
  30. 30.
    Ogino S, Nosho K, Kirkner GJ, et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut. 2009;58(1):90–6.PubMedCrossRefGoogle Scholar
  31. 31.
    • Karapetis CS, Khambata-Ford S, Jonker DJ, et al.: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359(17):1757–65. Key published paper showing lack of benefit from cetuximab in metastatic colorectal cancer from analysis of patients participating in the CO.18 randomized phase 3 trial. PubMedCrossRefGoogle Scholar
  32. 32.
    •• Ogino S, Meyerhardt JA, Irahara N, et al.: KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15(23):7322–9. This is a prospectively planned translational study from the CALGB89803 adjuvant colon cancer trial, analyzing the prognostic value of k-ras mutations. PubMedCrossRefGoogle Scholar
  33. 33.
    Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol. 2007;25(23):3456–61.PubMedCrossRefGoogle Scholar
  34. 34.
    Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the multicenter “RASCAL” study. J Natl Cancer Inst. 1998;90(9):675–84.PubMedCrossRefGoogle Scholar
  35. 35.
    Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85(5):692–6.PubMedCrossRefGoogle Scholar
  36. 36.
    Conlin A, Smith G, Carey FA, et al. The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma. Gut. 2005;54(9):1283–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Samowitz WS, Sweeney C, Herrick J, et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 2005;65(14):6063–9.PubMedCrossRefGoogle Scholar
  38. 38.
    • French AJ, Sargent DJ, Burgart LJ, et al.: Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008;14(11):3408–15. Study of associations between MMR and b-raf mutations in a cohort of clinical trial participants. PubMedCrossRefGoogle Scholar
  39. 39.
    • Tie J, Gibbs P, Lipton L, et al.: Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int J Cancer 2011;128(9):2075–84. This article describes how clinicopathological and molecular features can identify CRC patients with a higher prevalence of B-raf mutations. PubMedCrossRefGoogle Scholar
  40. 40.
    Branch P, Aquilina G, Bignami M, Karran P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature. 1993;362(6421):652–4.PubMedCrossRefGoogle Scholar
  41. 41.
    Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res. 1998;4(1):1–6.PubMedGoogle Scholar
  42. 42.
    Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247–57.PubMedCrossRefGoogle Scholar
  43. 43.
    •• Sargent DJ, Marsoni S, Monges G, et al.: Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28(20):3219–26. Article describing pooled analysis of the effect of MSI status on likelihood of benefit from adjuvant chemotherapy using tumor specimens from patients enrolled in randomized trials of adjuvant chemotherapy versus surgery alone. PubMedCrossRefGoogle Scholar
  44. 44.
    National Comprehensive Cancer Network (NCCN) Colon Cancer Guidelines Version 2.2011. Available at: Accessed February 2011.
  45. 45.
    Liang JT, Huang KC, Lai HS, et al. High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection. Int J Cancer. 2002;101(6):519–25.PubMedCrossRefGoogle Scholar
  46. 46.
    Phase III Randomized Study of Oxaliplatin, Leucovorin Calcium, and Fluorouracil With Versus Without Bevacizumab in Patients With Resected Stage II Colon Cancer and at High Risk for Recurrence Based on Molecular Markers (ECOG-E5202). Available at: = 443410&version = healthprofessional. Accessed Feburary 2011.
  47. 47.
    Bras-Goncalves RA, Rosty C, Laurent-Puig P, et al. Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. Br J Cancer. 2000;82(4):913–23.PubMedCrossRefGoogle Scholar
  48. 48.
    Tejpar S, Bosman F, Delorenzi M, et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial). J Clin Oncol. 2009;27:15s (suppl; abstr 4001).CrossRefGoogle Scholar
  49. 49.
    • Bertagnolli MM, Niedzwiecki D, Compton CC, et al.: Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27(11):1814–21. Analysis of the effect of mismatch repair dysfunction on outcomes in patients treated on the CALGB 89803 clinical trial. PubMedCrossRefGoogle Scholar
  50. 50.
    Fallik D, Borrini F, Boige V, et al. Microsatellite instability is a predictive factor of the tumor response to irinotecan in patients with advanced colorectal cancer. Cancer Res. 2003;63(18):5738–44.PubMedGoogle Scholar
  51. 51.
    Kim ST, Lee J, Park SH, et al. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemother Pharmacol. 2009;66(4):659–67.PubMedCrossRefGoogle Scholar
  52. 52.
    Kim ST, Lee J, Park SH, et al. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer. Med Oncol. 2009;27(4):1277–85.PubMedCrossRefGoogle Scholar
  53. 53.
    Zaanan A, Cuilliere-Dartigues P, Guilloux A, et al. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin. Ann Oncol. 2009;21(4):772–80.PubMedCrossRefGoogle Scholar
  54. 54.
    Kuebler JP, Wieand HS, O’Connell MJ, et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol. 2007;25(16):2198–204.PubMedCrossRefGoogle Scholar
  55. 55.
    Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004;350(23):2343–51.PubMedCrossRefGoogle Scholar
  56. 56.
    Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle. 2006;5(8):818–23.PubMedCrossRefGoogle Scholar
  57. 57.
    Jover R, Nguyen TP, Perez-Carbonell L, et al.: 5-Fluorouracil Adjuvant Chemotherapy Does Not Increase Survival in Patients with CpG Island Methylator Phenotype Colorectal Cancer. Gastroenterology 2010 Dec 24, In press.Google Scholar
  58. 58.
    Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol. 2004;22(3):529–36.PubMedCrossRefGoogle Scholar
  59. 59.
    Wei X, McLeod HL, McMurrough J, et al. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610–5.PubMedCrossRefGoogle Scholar
  60. 60.
    Seetharam R, Sood A, Basu-Mallick A, et al. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells. Anticancer Res. 2010;30(7):2531–8.PubMedGoogle Scholar
  61. 61.
    Lamas M, Duran G, Balboa E, et al. Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer. Pharmacogenomics. 2011;12(3):433–42.PubMedCrossRefGoogle Scholar
  62. 62.
    Yin M, Yan J, Martinez-Balibrea E, et al. ERCC1 and ERCC2 Polymorphisms Predict Clinical Outcomes of Oxaliplatin-Based Chemotherapies in Gastric and Colorectal Cancer: A Systemic Review and Meta-analysis. Clin Cancer Res. 2011;17(6):1632–40. Epub 2011 Jan 28.PubMedCrossRefGoogle Scholar
  63. 63.
    Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2(1):43–7.PubMedCrossRefGoogle Scholar
  64. 64.
    •• O’Connell MJ, Lavery I, Yothers G, et al.: Relationship between tumor gene expression and recurrence in four independent studies of patients with stage II/III colon cancer treated with surgery alone or surgery plus adjuvant fluorouracil plus leucovorin. J Clin Oncol 2010;28(25):3937–44. Article describing the analysis of genes from patients from four studies and identification of genes significantly associated with recurrence risk and chemotherapy benefit. PubMedCrossRefGoogle Scholar
  65. 65.
    Kerr D, Gray R, Quirke P, et al.: A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study. J Clin Oncol 27:15s, 2009 (suppl; abstr 4000)CrossRefGoogle Scholar
  66. 66.
    •• Salazar R, Roepman P, Capella G, et al.: Gene expression signature to improve prognosis prediction of stage II and III colorectal cancer. J Clin Oncol 2010;29(1):17–24. Article describing the development of the ColoPrint prognostic classifier and the development and validation of an optimal set of 18 genes. PubMedCrossRefGoogle Scholar
  67. 67.
    Rosenberg R, Maak M, Nitsche S, et al.: Independent validation of a prognostic genomic profile (ColoPrint) for stage II colon cancer (CC) patients. J Clin Oncol 29: 2011 (suppl 4; abstr 358).Google Scholar
  68. 68.
    • Figueredo A, Coombes ME, Mukherjee S: Adjuvant therapy for completely resected stage II colon cancer. Cochrane Database Syst Rev 2008(3):CD005390. Cochrane review of the benefit of adjuvant chemotherapy for stage II colon cancer. Google Scholar
  69. 69.
    Gray R, Barnwell J, McConkey C, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet. 2007;370(9604):2020–9.PubMedCrossRefGoogle Scholar
  70. 70.
    Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17(5):1356–63.Google Scholar
  71. 71.
    Allegra CJ, Yothers G, O’Connell MJ, et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2010;29(1):11–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: a systematic review from the Cancer Care Ontario Program in evidence-based care’s gastrointestinal cancer disease site group. J Clin Oncol. 2004;22(16):3395–407.PubMedCrossRefGoogle Scholar
  73. 73.
    Ogino S, Nosho K, Irahara N, et al. Prognostic significance and molecular associations of 18q loss of heterozygosity: a cohort study of microsatellite stable colorectal cancers. J Clin Oncol. 2009;27(27):4591–8.PubMedCrossRefGoogle Scholar
  74. 74.
    Russo A, Bazan V, Iacopetta B, et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol. 2005;23(30):7518–28.PubMedCrossRefGoogle Scholar
  75. 75.
    Popat S, Chen Z, Zhao D, et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol. 2006;17(12):1810–7.PubMedCrossRefGoogle Scholar
  76. 76.
    Edler D, Glimelius B, Hallstrom M, et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol. 2002;20(7):1721–8.PubMedCrossRefGoogle Scholar
  77. 77.
    Allegra CJ, Paik S, Colangelo LH, et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes’ B and C colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol. 2003;21(2):241–50.PubMedCrossRefGoogle Scholar
  78. 78.
    • Sargent D, Sobrero A, Grothey A, et al.: Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2009;27(6):872–7. Large analysis of 20,800 patients from the ACCENT database, analyzing the benefits of adjuvant chemotherapy for resected stage II and III colon cancer. PubMedCrossRefGoogle Scholar
  79. 79.
    Elsaleh H, Powell B, Soontrapornchai P, et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: impact on survival of 388 patients with Dukes’ C colon carcinoma. Oncology. 2000;58(1):52–9.PubMedCrossRefGoogle Scholar
  80. 80.
    Elsaleh H, Powell B, McCaul K, et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res. 2001;7(5):1343–9.PubMedGoogle Scholar
  81. 81.
    Johnston PG, Fisher ER, Rockette HE, et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol. 1994;12(12):2640–7.PubMedGoogle Scholar
  82. 82.
    Westra JL, Hollema H, Schaapveld M, et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol. 2005;16(10):1646–53.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2011

Authors and Affiliations

  1. 1.Department of Medical OncologyRoyal Melbourne HospitalParkvilleAustralia
  2. 2.Ludwig Colorectal Cancer InitiativeLudwig Institute for Cancer Research Melbourne - Parkville BranchMelbourneAustralia
  3. 3.Division of Cancer MedicinePeter MacCallum Cancer Centre, St. Andrews PlaceEast MelbourneAustralia
  4. 4.Department of MedicineUniversity of MelbourneMelbourneAustralia

Personalised recommendations